Data collected in the National HPV Monitoring Program has been included in the following publications and reports:
- Machalek D, Rees H, Chikandiwa A, Munthali R, Travill D, Mbulawa Z, Petoumenos K, Delany-Moretlwe S, Kaldor J; HOPE Study team. Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: study protocol and rationale for a programatic before-after design. BMJ Open. 2022 Feb: 12(2):e059968.
- Atchison S, Shilling H, Balgovind P, Machalek DA, Hawkes D, Garland SM, Saville M, Murray G, Molano M, Danielewski J, Phillips. Evaluation of the Roche MagNA Pure 96 nucleic acid extraction platform for the Seegene Anyplex II HPV28 detection assay. J Appl Microbiol. 2021 Nov: 131(5):2592-2599.
- Shilling H, Garland SM, Atchison S, Cornall AM, Brotherton JML, Bateson D, McNamee K, Kaldor JM, Hocking JS, Chen MY, Fairley CK, McNulty A, Bell C, Marshall L, Ooi C, Skinner SR, Murry G, Molano M, Tabrizi S, Machalek, DA. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction. Vaccine. 2021 Aug 9; 39(34): 4856-4863.
- Brotherton JML, Wheeler C, Clifford GM, Elfstrom M, Saville M, Kaldor J, Machalek DA. Surveillance systems for monitoring cervical cancer elimination efforts: Focus on HPV infection, cervical dysplasia, cervical screening and treatment. Prev Med. 2021 Mar: 144: 106293.
- Chow EPF, Tabrizi S, Fairley CK, Wigan R, Machalek DA, Garland SM, Cornall A, Atchison S, Hocking JS, Bradshaw CS, Balgovind P, Murray G, Chen MY. Fall in human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study. Lancet Infectious Diseases 2021.
- Shilling H, Murray G, Brotherton JML, et al. Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening. Vaccine 2020; 38:1186-93.
- Machalek DA, Roberts JM, Garland SM, et al. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program. Med J Aust 2019;211(3):113-19. doi: 10.5694/mja2.50223
- Drolet M, Benard E, Perez N, Brisson M, Group HPVVIS. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019; 394:497-509.
- Chow EPF, Tabrizi SN, Fairley CK, Wigan R, Machalek DA, Regan DG, et al. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017. Vaccine. 2019;37(46):6907-14.
- Machalek DA, Garland SM, Brotherton JML, Bateson D, McNamee K, Stewart M, et al. Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination. J Infect Dis. 2018;217(10):1590-600.
- Machalek DA, Chow EP, Garland SM, et al. Human papillomavirus prevalence in unvaccinated heterosexual men after a national female vaccination program. J Infect Dis 2017; 215:202-8.
- Das R, Machalek DA, Molesworth EG, Garland SM. Using Facebook to recruit young Australian men into a cross-sectional human papillomavirus study. J Med Internet Res. 2017;19(11):e389.
- Garland SM, Molesworth EG, Machalek DA, Cornall AM, Tabrizi SN. How to best measure the effectiveness of male human papillomavirus vaccine programmes? Clin Microbiol Infect. 2015;21(9):834-41.
- NHMRC Centre of Research Excellence in Cervical Cancer Control. 2021 Cervical Cancer Elimination Progress Report: Australia’s progress towards the elimination of cervical cancer as a public health problem. Published online 26/3/2021, Melbourne, Australia.
- Machalek D, Shilling H. Human papillomavirus prevalence in women attending health services across Australia 2015–2018: Short Report, Melbourne: The Royal Women’s Hospital; 2019